Human Constitutive Androstane Receptor (isoform 3)
(NR1I3, CAR, CAR3)
Reporter Assay System

3x 32 Assays in 96-well Format
Product # IB00901-32

Technical Manual
(version 7.1b)

www.indigobiosciences.com
3006 Research Drive, Suite A1, State College, PA 16801, USA

Customer Service:
814-234-1919; FAX 814-272-0152
customerserv@indigobiosciences.com

Technical Service:
814-234-1919
technical@indigobiosciences.com
Human CAR3 Reporter Assay System
3x 32 Assays in 96-well Format

I. Description
• Constitutive Androstane Receptors ..............................................3
• The Human CAR3 Assay System...................................................4
• The Assay Chemistry.................................................................4
• Preparation of Test Compounds...................................................5
• Assay Scheme..............................................................................5
• Assay Performance.......................................................................6

II. Product Components & Storage Conditions ...................................8

III. Materials to be Supplied by the User.........................................8

IV. Assay Protocol
• A word about Antagonist-mode assay setup..................................9
  • DAY 1 Assay Protocol.................................................................9
  • DAY 2 Assay Protocol...............................................................11

V. Related Products........................................................................11

VI. Limited Use Disclosures............................................................12

APPENDIX 1: Example Scheme for Serial Dilution...........................13
I. Description

- Constitutive Androstane Receptors -

The family of human Constitutive Androstane Receptors (CAR, NR1I3) regulate the expression of genes involved in xenobiotic metabolism and transport in the liver, including CYP2B and 3A4, UGT1 and MDR. Studies from mouse models show that CAR is also involved in bile acid, thyroid hormone and HDL homeostasis\(^1\). The human CAR gene is subject to numerous alternative splicing events during pre-mRNA processing\(^2\). The 348 amino acid isoform 1 of human CAR (CAR1) is encoded by 9 exons comprising the DNA binding domain (DBD), hinge region, and a ligand binding domain (LBD). The primary sequence of CAR2 differs from CAR1 in that it contains a four amino acid (VSPT) insert, whereas CAR3, which is the predominant isoform expressed in the liver, contains a distinct five amino acid (APYLT) insert\(^1\).

These small sequence variations confer great functional complexity to the human CAR1, 2, and 3 isoforms, including distinct ligand utilization and activation profiles\(^4\). True to its name, CAR1 is constitutively active, but can be further regulated through ligand interactions, mainly via inverse-agonism. PK11195, clotrimazole, androstane, and 2-ethylhexyl diphenyl phosphate (EDP) exhibit moderate inverse-agonism of CAR1, but show no (or very low) activity against the other CAR isoforms. Unlike CAR1, CAR2 and CAR3 are not constitutively active, showing ligand-dependent activation of reporter genes linked to genetic response elements derived from CYP2B6 or CYP3A4 promoters\(^1\). Di(2-ethylhexyl) phthalate (DEHP) is a strong agonist of CAR2\(^3\), but has no activity towards CAR1 or CAR3. Conversely, 6-(4-chlorophenyl)imidazo[2,1-b]thiazole-5-carbaldehyde O-3,4-dichlorobenzyl)oxime (CITCO) is an exceptionally potent agonist of CAR3, but exhibits no activity against CAR1 or CAR2.

Interestingly, distinct activation profiles and ligand preferences are also a feature of mouse CAR (inducible activation) and rat CAR (constitutive activity). For example, 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP) and meclizine are potent agonists of mouse CAR, but exhibit no activity to rat CAR or the human CAR isoforms.

It is noteworthy, and a source of experimental confusion, that a number of xenobiotics characterized as activators of human CAR (including phenobarbital) actually modulate the receptor's activity via indirect mechanisms. In other words, such chemicals do not directly bind to CAR, rather, they impact the activity of upstream regulatory mechanisms that impinge on CAR activity. Hybrid nuclear receptors in which the native N-terminal DNA binding domain (DBD) has been substituted with the GAL4 DBD, such as is used in this reporter assay kit, likely will not be responsive to chemical modulators that act through indirect mechanisms.

The expression of human CAR1, 2 and 3 isoforms with their unique activation profiles, disparate responses to xenobiotics, and cross-species differences, can challenge the interpretation of bioactivity profiling data. However, given the importance of CAR activity in predicting drug-drug and drug-nutrient interactions, it is an endeavor worth undertaking.

**The Human CAR3 Assay System**

This nuclear receptor assay system utilizes proprietary non-human mammalian cells engineered to provide constitutive, high-level expression of Human Constitutive Androstane Receptor, isoform 3 (NR1I3), a ligand-dependent transcription factor commonly referred to as CAR3. These reporter cells utilize a modified version of human CAR3 in which the native N-terminal DNA binding domain (DBD) has been replaced with that of the GAL4-DBD. The human CAR3 ligand binding domain (LBD) is unaltered and fully functional. The reporter cells also incorporate a luciferase cDNA functionally linked to the GAL4-upstream activation sequence (UAS). Thus, quantifying expressed luciferase activity provides a sensitive surrogate measure of changes in CAR3 activity resulting from direct interaction between a treatment compound and the nuclear receptor.

Because this assay system expresses the [GAL4-DBD + hCAR3 LBD] hybrid receptor, the activity of modulators that act through indirect mechanisms (such as those that alter the phosphorylation status of the native N-terminal amino acid sequence of the CARs) may be dampened or go undetected.

Contrary to its name, human CAR3 is not constitutively active. Rather, isoform 3 of CAR exhibits ligand-dependent activation. Hence, the primary application of this reporter assay system is in the screening of test compounds to quantify any functional activity, either agonist or antagonist, that they may exert on human CAR3.

Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

INDIGO Bioscience’s Nuclear Receptor Reporter Assays are all-inclusive cell-based assay systems. In addition to CAR3 Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, a positive-control agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate.

**The Assay Chemistry**

INDIGO’s nuclear receptor reporter assay systems capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg²⁺-dependent reaction that consumes O₂ and ATP as co-substrates, and yields as products oxyluciferin, AMP, PPi, CO₂, and photon emission. Luminescence intensity of the reaction is quantified using a luminometer, and is reported in terms of Relative Light Units (RLU’s).

INDIGO’s Nuclear Receptor Reporter Assay Systems feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5 minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.
**Preparation of Test Compounds**

Most commonly, test compounds are solvated at high-concentration in DMSO, and these are stored as master stocks. Master stocks are then diluted to appropriate working concentrations immediately prior to setting up the assay. Users are advised to dilute test compounds to 2x-concentration stocks using **Compound Screening Medium (CSM)**, as described in Step 2 of the **Assay Protocol**. This method avoids the adverse effects of introducing high concentrations of DMSO into the assay. The final concentration of total DMSO carried over into assay reactions should never exceed 0.4%.

**NOTE:** CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment of the assay mixture. Nonetheless, high concentrations of extremely hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup, and are considered to be 'single-use' reagents.

**Assay Scheme**

**Figure 1.** Assay workflow. *In brief,* Reporter Cells are dispensed into wells of the assay plate and then immediately dosed with the user’s test compounds. Following 22 -24 hr incubation, treatment media are discarded and prepared Luciferase Detection Reagent (LDR) is added. Light emission from each assay well is quantified using a plate-reading luminometer.
**Assay Performance**

Figure 2. CITCO agonist dose-response of the CAR3 Assay.

Dose-response analyses of CAR3 Reporter Cells were performed according to the protocol provided in this Technical Manual. In addition, to assess the level of background signal contributed by non-specific factors that may cause activation of the luciferase reporter gene, "mock" reporter cells were prepared to contain only the luciferase vector (mock reporter cells are not provided with assay kits). CAR3 Reporter Cells and mock reporter cells were identically treated with CITCO using an assay concentration range generated in 2.5-fold increments (as described in Appendix 1): 2500, 1000, 400, 160, 64.0, 25.6, 10.2 and 0 nM. Luminescence was quantified using a GloMax-Multi+ luminometer. Average relative light units (RLU) and corresponding standard deviation (SD) values were determined for each treatment concentration ($n \geq 6$). Signal-to-background (S/B) and $Z'$ values were calculated as described by Zhang, et al. (1999). Non-linear regression analyses and $EC_{50}$ determination were performed using GraphPad Prism software.

RESULTS: CAR3 reporter cells treated with 2500 nM CITCO yielded a S/B of ~ 170 and a corresponding $Z' = 0.85$. Similarly treated mock reporter cells demonstrate no significant background luminescence (≤ 0.05% that of the reporter cells at $EC_{Max}$). Thus, luminescence results strictly through ligand-activation of the human CAR3 expressed in these reporter cells. These data confirm the robust performance of this CAR3 Reporter Assay System, and demonstrate its suitability for use in HTS applications.\(^1\)

**NOTE:** RLU values will vary slightly between different production lots of reporter cells, and can vary significantly between different makes and models of luminometers.


\[ Z' = 1 - \frac{3 \times (SD_{Reference} + SD_{Bkg})}{RLU_{Reference} - RLU_{Bkg}} \]
Human CAR3 Antagonist Assay

![Graph showing dose-dependent inhibition of CAR3 by CINPA-1](image)

**Figure 2b. CINPA-1 dose-dependent inhibition of CAR3**

Human CAR3 Reporter Cells were treated with ~EC$_{50}$ of CITCO and then challenged with 2-fold incremental concentrations of CINPA-1 (Tocris). The following concentrations were tested: 60, 30, 15, 7.5, 3.75, 1.88, 0.938 and 0 µM CINPA-1.
II. Product Components & Storage Conditions

This Human CAR3 Reporter Assay System contains materials to perform three distinct groups of assays in a 96-well plate format. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

The individual aliquots of Reporter Cells are provided as single-use reagents. Once thawed, reporter cells can NOT be refrozen or maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

Assay kits are shipped on dry ice. Upon receipt, individual kit components may be stored at the temperatures indicated on their respective labels. Alternatively, the entire kit may be further stored at -80°C.

To ensure maximal viability, “Reporter Cells” must be maintained at -80°C until immediately prior to use.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

<table>
<thead>
<tr>
<th>Kit Components</th>
<th>Amount</th>
<th>Storage Temp.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR3 Reporter Cells</td>
<td>3 x 0.60 mL</td>
<td>-80°C</td>
</tr>
<tr>
<td>Cell Recovery Medium (CRM)</td>
<td>1 x 10.5 mL</td>
<td>-20°C</td>
</tr>
<tr>
<td>Compound Screening Medium (CSM)</td>
<td>1 x 35 mL</td>
<td>-20°C</td>
</tr>
<tr>
<td>CITCO*, 4.0 mM (in DMSO)</td>
<td>1 x 30 µL</td>
<td>-20°C</td>
</tr>
<tr>
<td>(reference agonist for CAR3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detection Substrate</td>
<td>3 x 2.0 mL</td>
<td>-80°C</td>
</tr>
<tr>
<td>Detection Buffer</td>
<td>3 x 2.0 mL</td>
<td>-20°C</td>
</tr>
<tr>
<td>Plate frame</td>
<td>1</td>
<td>ambient</td>
</tr>
<tr>
<td>Snap-in, 8-well strips</td>
<td>12</td>
<td>ambient</td>
</tr>
<tr>
<td>(white, sterile, cell-culture ready)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* 6-(4-chlorophenyl)imidazo[2,1-b] thiazole-5-carbaldehyde O-3,4-dichlorobenzyl)oxime (CITCO)

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

**DAY 1**
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO2 incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8- or 12-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), or deep-well plates, or appropriate similar vessel for generating dilution series of reference compound(s) and test compound(s).
- antagonist reference compound (optional).

**DAY 2**
- plate-reading luminometer.
**IV. Assay Protocol**

Review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. **Steps 1-8** are performed on **Day 1**, requiring less than 2 hours to complete. **Steps 9-14** are performed on **Day 2**, and require less than 1 hour to complete.

- **A word about Antagonist-mode assay setup**

  Receptor inhibition assays expose the Reporter Cells to a constant, sub-maximal concentration (typically between EC$_{50}$ – EC$_{85}$) of a known agonist AND the test compound(s) to be evaluated for antagonist activity. This CAR3 Reporter Assay System kit includes a 4.0 mM stock solution of **CITCO**, a potent agonist of CAR3 that may be used to setup antagonist-mode assays. 400 nM CITCO typically approximates EC$_{55}$ in this reporter assay. Hence, it presents a reasonable assay concentration of agonist to be used when screening test compounds for inhibitory activity.

  We find that adding the reference agonist to the bulk suspension of Reporter Cells (i.e., prior to dispensing into assay wells) is the most efficient and precise method of setting up antagonist assays, and it is the method presented in **Step 5b** of the following protocol. Note that, in **Step 6**, 100 µl of treatment media is combined with 100 µl of pre-dispersed [Reporter Cells + agonist]. Consequently, one must prepare the bulk suspension of Reporter Cells to contain a 2x-concentration of the reference agonist. **APPENDIX 1** provides a dilution scheme that may be used as a guide when preparing cell suspension supplemented with a desired 2x-concentration of agonist.

<table>
<thead>
<tr>
<th>DAY 1 Assay Protocol: All steps must be performed using aseptic technique.</th>
</tr>
</thead>
</table>

1.) **Remove** Cell Recovery Medium (CRM) and **Compound Screening Medium (CSM)** from freezer storage and thaw in a 37°C water bath.

2.) **Prepare dilutions of treatment compounds:** Prepare Test Compound treatment media for **Agonist- or Antagonist-mode** screens.

   Total DMSO carried over into assay reactions should never exceed 0.4%.

   Note that, in **Step 6**, 100 µl of the prepared treatment media is added into assay wells that have been pre-dispensed with 100 µl of Reporter Cells. Hence, to achieve the desired final assay concentrations one must prepare treatment media with a 2x-concentration of the test and reference material(s). Use **CSM** to prepare the appropriate dilution series. Manage dilution volumes carefully. This assay kit provides 35 ml of CSM.

   **Preparing the positive control:** This CAR3 Reporter Assay System kit includes a 4.0 mM stock solution of **CITCO**, a potent agonist of CAR3 that may be used as a reference compound. The following 7-point treatment series, with concentrations presented in 2.5-fold decrements, provides a suitable dose-response: 2500, 1000, 400, 160, 64, 25.6, and 10.2 nM, and including a 'no treatment' control. **APPENDIX 1** provides an example for generating such a dilution series.

3.) **Rapid Thaw of the Reporter Cells:** First, retrieve the tube of CRM from the 37°C water bath and sanitize the outside with a 70% ethanol swab.

   **Second,** retrieve Reporter Cells from -80°C storage. Perform a rapid thaw of the frozen cells by transferring a 3.0 ml volume of 37°C CRM into the tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37°C water bath for 3 - 10 minutes. The resulting volume of cell suspension will be 3.6 ml.

   **Third,** work in the cell culture hood to carefully mount four sterile 8-well strips into the blank assay plate frame. Strip-wells are fragile. Note that they have keyed ends (square and round), hence, they will fit into the plate frame in only one orientation.
4.) Retrieve the tube of Reporter Cell Suspension from the water bath. Sanitize the outside surface of the tube with a 70% alcohol swab.

5.) **a. Agonist-mode assays.** Invert the tube of Reporter Cells several times to disperse cell aggregates and gain an homogenous cell suspension. Without delay, dispense 100 µl of cell suspension into each well of the assay plate.

   ~ or ~

b. **Antagonist-mode assays.** Invert the tube of Reporter Cells several times to disperse any cell aggregates, and to gain an homogenous cell suspension. Supplement the bulk suspension of Reporter Cells with the desired 2x-concentration of reference agonist (refer to "A word about antagonist-mode assay setup", pg. 8). Dispense 100 µl of cell suspension into each well of the assay plate.

   **NOTE 5.1:** Take special care to prevent cells from settling during the dispensing period. Allowing cells to settle during the transfer process, and/or lack of precision in dispensing uniform volumes across the assay plate will cause well-to-well variation (= increased Standard Deviation) in the assay.

   **NOTE 5.2:** Users sometimes prefer to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed (100 µl/well) into a clear 96-well cell culture treated assay plate, followed by 100 µl/well of CSM (as in Step 6). Incubated overnight in identical manner to those reporter cells contained in the white assay plate.

6.) Dispense 100 µl of 2x-concentration treatment media into appropriate assay wells.

7.) Transfer the assay plate into a 37°C, humidified 5% CO₂ incubator for 22 - 24 hours.

   **NOTE:** Ensure a high-humidity (≥ 85%) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

8.) For greater convenience on Day 2, retrieve **Detection Substrate and Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.
DAY 2 Assay Protocol: Subsequent manipulations do not require special regard for aseptic technique, and may be performed on a bench top.

9.) 30 minutes before intending to quantify CAR3 activity, remove Detection Substrate from the refrigerator and place them in a low-light area so that it may equilibrate to room temperature. Gently invert the tube several times to ensure an homogenous solution.

\[ \text{NOTE: Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4}^\circ\text{C, a room temperature water bath may be used to expedite thawing.} \]

10.) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, or less.

11.) Immediately before proceeding to Step 12: To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml volume of Luciferase Detection Reagent (LDR). Mix gently to avoid foaming.

12.) After 22-24 hours of incubation, remove media contents from each well.

\[ \text{NOTE: Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Do not touch the well bottom, or run the tip of the aspiration device around the bottom circumference of the assay well. Such practices will result in destruction of the reporter cells and greatly increased well-to-well variability. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using an 8-pin manifold (e.g., Wheaton Science Microtest Syringe Manifold, # 851381) affixed to a vacuum-trap apparatus.} \]

13.) Add 100 µl of LDR to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes. Do not shake the assay plate during this period.

14.) Quantify luminescence.
### Human CAR1 Assay Products

<table>
<thead>
<tr>
<th>Product No.</th>
<th>Product Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>IB00911-32</td>
<td>Human CAR1 Reporter Assay System 3x 32 assays in 96-well format</td>
</tr>
<tr>
<td>IB00911</td>
<td>Human CAR1 Reporter Assay System 1x 96-well format assay</td>
</tr>
<tr>
<td>IB00912</td>
<td>Human CAR1 Reporter Assay System 1x 384-well format assays</td>
</tr>
</tbody>
</table>

### Human CAR3 Assay Products

<table>
<thead>
<tr>
<th>Product No.</th>
<th>Product Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>IB00901-32</td>
<td>Human CAR3 Reporter Assay System 3x 32 assays in 96-well format</td>
</tr>
<tr>
<td>IB00901</td>
<td>Human CAR3 Reporter Assay System 1x 96-well format assay</td>
</tr>
<tr>
<td>IB00902</td>
<td>Human CAR3 Reporter Assay System 1x 384-well format assays</td>
</tr>
</tbody>
</table>

### Mouse CAR Assay Products

<table>
<thead>
<tr>
<th>Product No.</th>
<th>Product Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>M00901-32</td>
<td>Mouse CAR Reporter Assay System 3x 32 assays in 96-well format</td>
</tr>
<tr>
<td>M00901</td>
<td>Mouse CAR Reporter Assay System 1x 96-well format assay</td>
</tr>
<tr>
<td>M00902</td>
<td>Mouse CAR Reporter Assay System 1x 384-well format assays</td>
</tr>
</tbody>
</table>

Bulk volumes of assay reagents may be custom manufactured to accommodate any scale of HTS. Please Inquire.
LIVE Cell Multiplex (LCM) Assay

<table>
<thead>
<tr>
<th>Product No.</th>
<th>Product Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCM-01</td>
<td>Reagent volumes sufficient to perform 96 Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats</td>
</tr>
<tr>
<td>LCM-05</td>
<td>Reagent in 5x-bulk volume to perform 480 Live Cell Assays in any combination of 1x96-, 2x48-, or 3x32-well assay plate formats</td>
</tr>
<tr>
<td>LCM-10</td>
<td>Reagent in 10x-bulk volume to perform 960 Live Cell Assays in any combination of 1x96-, 2x48-, or 3x32-well assay plate formats</td>
</tr>
</tbody>
</table>

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Limited Use Disclosures

Products commercialized by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic or diagnostic use in humans. Other applications of this product may require license(s) from others.

“CryoMite” is a Trademark™ of INDIGO Biosciences, Inc. (State College, PA, USA)

Product prices, availability, specifications and claims are subject to change without prior notice.

Copyright © INDIGO Biosciences, Inc. All Rights Reserved.

APPENDIX 1

Example scheme for the serial dilution of CITCO reference agonist, and the setup of a CAR3 dose-response assay.

1 For convenience, serial dilutions may be made directly in a dual-function solution basin (Healthrow Scientific) or a deep 96-well plate.